Mode
Text Size
Log in / Sign up
N/A N=64 Randomized Double-blind Treatment

Talocrural Joint Manipulation in Stroke

Stroke

Enrolled (actual)
64
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Overall Stability Index Measurement — 17.5; 9 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Talocrural Joint Manipulation (Other); Placebo Talocrural Joint Manipulation (Other)
Age
Adult, Older Adult · 45+ yrs
Sex
All
Sponsor
Bitlis Eren University
Primary completion
Nov 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Stability Index Measurement
17.5; 9
SECONDARY
Mediolateral Stability Index Measurement
6.96; 4.87
SECONDARY
Anteroposterior Stability Index Measurement
10; 5.5
SECONDARY
Ankle Dorsiflexion Range of Motion Measurement With Knee in Extended and Flexed Positions
13; 22.5; 10; 18.5

Summary

The primary aim of the study is to investigate the effect of talocrural joint manipulation on the static balance of patients with stroke. The secondary aim of this study is to investigate the effect of talocrural joint manipulation on the dorsiflexion range of motion of patients with stroke.

Eligibility Criteria

Inclusion Criteria

  • 1. Two months or longer elapsed since the stroke,
  • 2. A Mini-Mental State Examination score of 24 or higher,
  • 3. The ability to stand independently for 20 seconds or more,
  • 4. The ability to walk independently for 10 meters with the use of walking aids or orthoses if necessary,
  • 5. Being between 45 and 75 years of age,
  • 6. Having a Brunnstrom stage of 4 or above

Exclusion Criteria

  • 1. The presence of severe osteoarthritis in the lower extremity,
  • 2. The presence of cancer or diabetic neuropathy,
  • 3. The presence of vestibular disorder,
  • 4. The presence of lower extremity ulceration or amputation,
  • 5. History of vertigo,
  • 6. Alcohol consumption within the last 24 hours,
  • 7. Hemodynamic instability,
  • 8. Diagnosis of posterior circulation stroke involving the basilar artery and cerebellum,
  • 9. The presence of other neurological disorders (such as multiple sclerosis, Parkinson's disease),
  • 10. Having experienced an acute lower extremity injury in the last six weeks,
  • 11. History of lower extremity surgery
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06523010). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search